What did @fabianafreitas actually say?
Honestly? Almost nothing, in words. The entire transcript is variations of "look at this" repeated with escalating excitement. There are no specific claims about dosage, weight lost, timeline, or mechanism. What the video communicates is purely visual and emotional: a before-and-after or mirror moment that clearly impressed the creator and, based on 456,000 views, a lot of viewers too.
That matters, because the implied message of a GLP-1 progress video carries real informational weight even without spoken claims. Viewers fill in the blanks. When someone films their own body with that level of excitement under the hashtag #mounjaro, the implicit message is: this drug caused a dramatic physical transformation. That framing deserves scrutiny even when no words back it up.
Does the science back up the implied transformation claim?
Yes, actually, tirzepatide, the active ingredient in Mounjaro, does produce meaningful weight loss in a substantial portion of users. The data here is legitimately strong, which is not something you can say about most weight loss interventions.
The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) followed 2,539 adults with obesity over 72 weeks. Participants on the highest dose (15 mg weekly) lost an average of 20.9% of body weight. That is not a rounding error. For context, participants on placebo lost about 3.1%. A separate SURMOUNT-2 trial (Garvey et al., 2023, The Lancet) showed similar results in people with type 2 diabetes, though with somewhat smaller magnitude.
So a person visibly excited about their body changes after starting Mounjaro? That tracks with what the clinical literature shows is possible for a meaningful percentage of users.
What did the video get wrong, or right?
There is nothing to fact-check as false here, because no factual claims were made. That cuts both ways. The creator did not spread misinformation about dosing, did not claim Mounjaro treats or cures a disease, and did not make any comparative claims about compounded versus brand-name versions. Credit where it is due.
The risk is different: the video contributes to a genre of content that makes GLP-1 results look universally dramatic. Not everyone loses 20% of body weight. SURMOUNT-1 showed that roughly 1 in 3 participants on the highest dose lost 25% or more, which means roughly 2 in 3 did not hit that threshold. Response varies considerably based on baseline metabolic health, adherence, dietary behavior, and individual pharmacology.
Progress videos, even genuine ones, create availability bias. Viewers remember the dramatic results and underestimate how much individual variation exists. That is not the creator's fault specifically, but it is the real-world effect of this content category at scale.
What should you actually know?
If you are considering Mounjaro or tirzepatide for weight management, a few things are worth understanding beyond the hype cycle.
- Tirzepatide is a dual GIP and GLP-1 receptor agonist, which mechanically distinguishes it from semaglutide (Ozempic, Wegovy). The dual action appears to contribute to its stronger weight loss signal in head-to-head comparisons (Frías et al., 2021, NEJM).
- Side effects are real and common. In SURMOUNT-1, roughly 40-50% of participants on active doses reported nausea, vomiting, or diarrhea at some point. Most were mild to moderate and resolved over time, but they are not trivial.
- Weight often returns after stopping. A discontinuation study (SURMOUNT-4, Aronne et al., 2024, JAMA) showed participants regained about two-thirds of their lost weight within a year of stopping tirzepatide.
- Mounjaro is FDA-approved for type 2 diabetes. Zepbound is the FDA-approved brand for chronic weight management. They contain the same molecule at similar doses, but they are not interchangeable in regulatory terms, and compounded versions are a separate category entirely.
- A telehealth provider or physician should evaluate whether GLP-1 therapy is appropriate for your specific health profile before you start.